Alinea Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Alinea Pharmaceuticals was founded recently around three in-licensed development programs, encompassing a Phase II-ready molecule to treat diabetic complications, a set of leads against a novel serum glucose-regulating target of significant interest to Big Pharma, and a research program around novel methods for lipid control.
You may also be interested in...
The Double-edged Sword of Diabetes Drug Development
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.